ACTIMMUNE in Intermediate Osteopetrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 22, 2016

Primary Completion Date

March 11, 2019

Study Completion Date

April 11, 2019

Conditions
Osteopetrosis
Interventions
DRUG

Interferon gamma-1b

gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly

Trial Locations (2)

55454

University of Minnesota, Minneapolis

90502

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance

All Listed Sponsors
collaborator

University of Minnesota

OTHER

collaborator

Horizon Pharma Ireland, Ltd., Dublin Ireland

INDUSTRY

lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

NCT02666768 - ACTIMMUNE in Intermediate Osteopetrosis | Biotech Hunter | Biotech Hunter